secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-09-29T14:31:04+00:00
Accession:  0001178913-26-004645
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Silexion Therapeutics reprices series E warrants to $0.2603, expects about $0.84M gross proceeds
--------------------------------------------------------------------------------

- Silexion Therapeutics entered a Sept 28, 2026 inducement letter with holders of 3,216,928 series E warrants to exercise at a reduced $0.2603/share price.
- The warrant exercise is expected to raise about $0.84 million gross, before H.C. Wainwright fees; closing is expected on or about Sept 29, 2026.
- Silexion will issue Series F and Series G warrants for up to 6,433,856 ordinary shares at $0.2603/share; Series F lasts five years, Series G 24 months after conditions.
- H.C. Wainwright & Co. is exclusive placement agent, earning a 7.0% cash fee, 1.0% management fee, and up to 225,185 placement agent warrants at $0.3254/share.
- Silexion also cut the exercise price for all outstanding series E warrants covering 3,846,161 ordinary shares to $0.2603/share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004645/0001178913-26-004645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004645/zk2636167.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-004645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer